Physicians Face Growing Pressure to Learn Cannabis Medicine

The Training Gap Is Operational, Not Theoretical

Fewer than 10 percent of U.S. medical schools include endocannabinoid system instruction in their curricula, even as cannabis patient registries have grown 40 percent since 2023. That mismatch leaves primary-care physicians fielding questions they weren't trained to answer. Patients in states like Florida, Pennsylvania, and Ohio routinely ask their doctors about THC-to-CBD ratios, terpene profiles, and dosing schedules—questions most MDs can't address without after-hours research or third-party CME courses.

The operational problem is straightforward. Physicians who can't discuss cannabinoids competently lose patient trust or refer out to cannabis-specific clinics, fragmenting care. In competitive primary-care markets, that referral represents lost revenue and continuity. The clinical risk? Equally concrete. Patients dose themselves using Reddit threads and budtender advice when their doctors stay silent.

For context on how this education deficit shapes state-level program design, see the CannIntel topic hub on medical cannabis physician education.

CME Providers Fill the Void, But Inconsistently

Continuing medical education platforms now offer 50-plus cannabis-focused courses, but quality and rigor vary wildly. Some programs are underwritten by MSOs with obvious commercial angles; others are peer-reviewed and accredited by state medical boards. Physicians report spending 8 to 20 hours on self-directed learning just to reach baseline competence in cannabinoid pharmacology.

The lack of standardized training creates a two-tier system: doctors in legal states who invest the time, and doctors in prohibition states who remain entirely unprepared for federal rescheduling or interstate practice.

That bifurcation will become a liability if the DEA finalizes its Schedule III proposal for cannabis. Interstate telemedicine rules and reciprocity frameworks assume a baseline of clinical knowledge that most physicians simply don't have. A Pennsylvania internist might complete 12 CME hours while a Texas counterpart has zero exposure—a patchwork that won't scale when federal reform arrives.

What Happens When Federal Rescheduling Lands

If cannabis moves to Schedule III, the FDA will expect prescribers to treat it like any other controlled therapeutic—which requires actual pharmacological fluency. That shift would likely trigger mandatory CME requirements in many states, similar to opioid prescribing rules rolled out after 2016. Physicians who wait for that mandate will be scrambling. Those who start now? They'll have a two-year head start on patient acquisition and clinical confidence.

The competitive read is simple: primary-care groups and independent practitioners who build cannabis competency today will capture referrals and retain patients when federal reform formalizes the market. Doctors who punt to dispensary staff or avoid the topic altogether will lose ground to competitors who can discuss THCA, myrcene, and dose titration fluently.

Rescheduling isn't the only forcing function. Insurers are beginning to cover cannabis for specific indications in states like New York and New Jersey, which means prior-authorization paperwork and ICD-10 coding. Physicians who can't document a clinical rationale for cannabinoid therapy won't be able to bill those cases, even when coverage exists.